Charles River Laboratories International Cash Flow Statement
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Charles River Laboratories International free cash flow
In fiscal 2025, Charles River Laboratories International generated $737.6 million of operating cash flow and spent $219.2 million on capital expenditures. That left free cash flow of $518.5 million, a free-cash-flow margin of 12.9% of revenue. Free cash flow was up 3.4% from the prior year's $501.6 million.
Charles River Laboratories International returned $360.7 million to shareholders through share repurchases, equal to 70% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Charles River Laboratories International cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-27 | FY 20242024-12-28 | FY 20232023-12-30 | FY 20222022-12-31 | FY 20212021-12-25 | FY 20202020-12-26 | FY 20192019-12-28 | FY 20182018-12-29 | FY 20172017-12-30 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -142.16M | 25.29M | 480.37M | 492.61M | 398.84M | 365.31M | 254.06M | 228.72M | 125.45M | 156.37M |
| Net Income growth (YoY) | -662.11% | -94.74% | -2.48% | +23.51% | +9.18% | +43.79% | +11.08% | +82.32% | -19.77% | +3.49% |
| Depreciation & Amortization | 403.31M | 361.74M | 314.12M | 303.87M | 265.54M | 234.92M | 198.09M | 161.78M | 131.16M | 126.66M |
| Stock-Based Compensation | 71.08M | 69.89M | 72.05M | 73.62M | 71.47M | 56.34M | 57.27M | 47.35M | 44.00M | 43.64M |
| Change in Working Capital | -48.31M | 42.69M | -137.91M | -174.09M | -20.29M | -74.61M | -3.57M | -11.19M | -74.55M | -26.03M |
| Operating Cash Flow | 737.65M | 734.58M | 683.90M | 619.64M | 760.80M | 546.58M | 480.94M | 441.14M | 318.07M | 316.90M |
| Capital Expenditures | -219.15M | -232.97M | -318.53M | -324.73M | -228.77M | -166.56M | -140.51M | -140.05M | -82.43M | -55.29M |
| Investing Cash Flow | -209.32M | -245.09M | -563.15M | -607.92M | -1.44B | -601.54M | -681.50M | -955.00M | -72.59M | -692.67M |
| Share Repurchases | -360.67M | -119.17M | -24.16M | -38.65M | -40.71M | -23.98M | -18.09M | -13.85M | -106.91M | -12.27M |
| Debt Issued | 1.23B | 1.08B | 776.35M | 2.95B | 6.95B | 2.23B | 3.36B | 2.76B | 236.86M | 1.04B |
| Debt Repaid | -1.35B | -1.49B | -851.68M | -2.93B | -6.24B | -2.20B | -3.12B | -2.20B | -372.44M | -656.64M |
| Financing Cash Flow | -536.73M | -550.93M | -85.52M | -42.40M | 672.60M | 47.25M | 231.94M | 558.06M | -208.48M | 380.76M |
| Net Change in Cash | 10.43M | -78.91M | 43.27M | -5.10M | 13.20M | -6.93M | 42.73M | 30.99M | 46.44M | -69.00K |
| Free Cash Flow | 518.49M | 501.61M | 365.37M | 294.91M | 532.03M | 380.01M | 340.42M | 301.09M | 235.64M | 261.61M |
This table shows 10 annual periods of Charles River Laboratories International's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CRL's reporting calendar. What is a cash flow statement?